View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Abivax: 1 director

A director at Abivax sold after exercising options/sold 1,104,640 shares at 54.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
 PRESS RELEASE

Eramet: Increased focus on operational efficiency following a highly p...

Eramet: Increased focus on operational efficiency following a highly pressured H1 2025 Paris, 30 July 2025, 6:30 p.m. PRESS RELEASE Eramet: Increased focus on operational efficiency following a highly pressured H1 2025 Safety performance remained strong in H1 2025, with a Group TRIFR1 of 0.6 Adjusted EBITDA (excluding SLN)2 at €191m, down 45% vs. H1 2024, primarily from the reduced contribution of PT WBN (-€92m, representing nearly 2/3 of the decline) attributable to: The planned start of new mining production sites at Weda Bay in Indonesia, compounded by constrained operating permit,...

 PRESS RELEASE

Eramet : priorité à l’efficacité opérationnelle après un 1er semestre ...

Eramet : priorité à l’efficacité opérationnelle après un 1er semestre 2025 sous forte pression Paris, le 30 juillet 2025, 18h30 COMMUNIQUE DE PRESSE Eramet : priorité à l’efficacité opérationnelle après un 1er semestre 2025 sous forte pression Solide performance en matière de sécurité au S1 2025, avec un TF21 Groupe de 0,6 EBITDA ajusté (hors SLN)2 à 191 M€ en baisse de 45 % par rapport au S1 2024, principalement en raison de la contribution réduite de PT WBN (- 92 M€, soit près de 2/3 de la baisse) s’expliquant par : Le démarrage prévu de nouveaux sites de production minière à Weda B...

Martial Descoutures
  • Martial Descoutures

Abivax : A well-deserved success, Outperform confirmed

We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch